Curis announces extended funding for neurological disorders from Wyeth

[Guest guest]

(Note to new members: We have followed the developments of Sonic

Hedgehog Protein here at for several years.)

Curis Announces Receipt of Extended Funding from Wyeth

http://phx.corporate-ir.net/phoenix.zhtml?c=123198 & p=irol-

newsArticle & t=Regular & id=784992 &

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 21, 2005--Curis, Inc.

(NASDAQ: CRIS), a therapeutic drug development company, today

announced that Wyeth has exercised its option under the 2004

agreement to extend funding to continue development of therapeutic

applications of the Hedgehog agonist with a primary focus on

neurological disorders. By exercising this option, Wyeth has agreed

to extend the research term by one year through February 9, 2007

(previously February 9, 2006). Curis expects Wyeth to select a

development candidate in the next twelve to eighteen months, and to

file an investigational new drug, or IND, application approximately

twelve months thereafter.

" We are encouraged by the continued dedication that Wyeth has shown

to the Hedgehog agonist program for neurological disorders. The

extension of funding for the program serves as a validation of the

progress made to date on this program, and we look forward to working

with Wyeth to select a development candidate for stroke and other

neurological disorders, " said R. Passeri, President and Chief

Executive Officer of Curis, Inc. " By meeting with Wyeth scientists on

a quarterly basis, Curis is able to learn more about the late

preclinical development process, which may prove to be invaluable at

a later date when Curis prepares to move its own products from

preclinical development into the clinic. "